Strategies for containing an emerging influenza pandemic in Southeast Asia

Nature

Volumn 437, Issue 7056, 2005, Pages 209-214

  Ferguson, Neil M ^a   Cummings, Derek A T ^b   Cauchemez, Simon ^c   Fraser, Christophe ^a   Riley, Steven ^d   Meeyai, Aronrag ^a   Iamsirithaworn, Sopon ^e   Burke, Donald S ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c INSERM   (France)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; MUTAGENESIS; PATHOLOGY; PUBLIC POLICY; STRATEGIC PLANNING; VIRUSES;

H5N1; HUMAN-TO-HUMAN TRANSMISSION; INFLUENZA PANDEMIC; MUTATION;

DISEASE CONTROL;

ANTIVIRUS AGENT;

BIRD; INFLUENZA; PUBLIC HEALTH; VIRUS;

ARTICLE; DISEASE TRANSMISSION; ENDEMIC DISEASE; FEASIBILITY STUDY; FOWL; GROUP PSYCHOLOGY; HEALTH CARE POLICY; INFLUENZA; INFLUENZA VIRUS A; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; SIMULATION; SOUTHEAST ASIA; VIRUS MUTATION; AGE DISTRIBUTION; ANIMAL; BIOLOGICAL MODEL; CLASSIFICATION; COMPUTER SIMULATION; CONTACT EXAMINATION; GENETIC REASSORTMENT; GENETICS; HUMAN; INFECTION CONTROL; METHODOLOGY; MUTATION; PATHOGENICITY; PHYSIOLOGY; POPULATION DENSITY; PROBABILITY; SENSITIVITY AND SPECIFICITY; STANDARD; THAILAND; TIME; TRAVEL; VIRUS REPLICATION; VIRUS SHEDDING;

ASIA; EASTERN HEMISPHERE; EURASIA; SOUTHEAST ASIA; WORLD;

AVES; INFLUENZA A VIRUS;

AGE DISTRIBUTION; ANIMALS; ANTIVIRAL AGENTS; ASIA, SOUTHEASTERN; COMMUNICABLE DISEASE CONTROL; COMPUTER SIMULATION; CONTACT TRACING; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; MUTATION; POPULATION DENSITY; PROBABILITY; QUARANTINE; REASSORTANT VIRUSES; SENSITIVITY AND SPECIFICITY; THAILAND; TIME FACTORS; TRAVEL; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 23844436610     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature04017     Document Type: Article

References (37)

1. World Health Organisation. Avian influenza: assessing the pandemic threat. 〈http://www.who.int/csr/disease/influenza/WHO_CDS_2005_29/en/index. html〉 (2005).
2. Abbott, A. & Pearson, H. Fear of human pandemic grows as bird flu sweeps through Asia. Nature 427, 472-473 (2004).
3. Spicer, C. C. & Lawrence, C. J. Epidemic influenza in Greater London. J. Hyg. (Lond.) 93, 105-112 (1984).
4. Fleming, D. M., Zambon, M., Bartelds, A. I. M. & de Jong, J. C. The duration and magnitude of influenza epidemics: A study of surveillance data from sentinel general practices in England, Wales and the Netherlands. Eur. J. Epidemiol. 15, 467-473 (1999).
5. Mills, C. E., Robins, J. M. & Lipsitch, M. Transmissibility of 1918 pandemic influenza. Nature 432, 904-906 (2004).
6. Anderson, R. M. & May, R. M. Infectious Diseases of Humans: Dynamics and Control (Oxford Univ. Press, Oxford, 1992).
7. Stohr, K. & Esveld, M. Will vaccines be available for the next influenza pandemic? Science 306, 2195-2196 (2004).
8. Leneva, I. A., Roberts, N., Govorkova, E. A., Goloubeva, O. G. & Webster, R. G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 48, 101-115 (2000).
9. Brooks, M. J., Sasadeusz, J. J. & Tannock, G. A. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr. Opin. Pulm. Med. 10, 197-203 (2004).
10. Coombes, R. UK stocks up on antiviral drug to tackle flu outbreak. Br. Med. J. 330, 495 (2005).
11. Longini, I. M. Jr, Halloran, M. E., Nizam, A. & Yang, Y. Containing pandemic influenza with antiviral agents. Am. J. Epidemiol. 159, 623-633 (2004).
12. Viboud, C. et al. Risk factors of influenza transmission in households. Br. J. Gen. Pract. 54, 684-689 (2004).
13. Principi, N., Esposito, S., Gasparini, R., Marchisio, P. & Crovari, P. Burden of influenza in healthy children and their households. Arch. Dis. Child. 89, 1002-1007 (2004).
14. Heymann, A., Chodick, G., Reichman, B., Kokia, E. & Laufer, J. Influence of school closure on the incidence of viral respiratory diseases among children and on health care utilization. Pediatr. Infect. Dis. J. 23, 675-677 (2004).
15. Hayden, F. G. et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J. Clin. Invest. 101, 643-649 (1998).
16. Elveback, L. R. et al. An influenza simulation model for immunization studies. Am. J. Epidemiol. 103, 152-165 (1976).
17. Longini, I. M. Jr, Koopman, J. S., Haber, M. & Cotsonis, G. A. Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. Am. J. Epidemiol. 128, 845-859 (1988).
18. Fox, J. P., Hall, C. E., Cooney, M. K & Foy, H. M. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am. J. Epidemiol. 116, 212-227 (1982).
19. Ferguson, N. M., Fraser, C., Donnelly, C. A., Ghani, A. C. & Anderson, R. M. Public health risk from the avian H5N1 influenza epidemic. Science 304, 968-969 (2004).
20. Riley, S. et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: Impact of public health interventions. Science 300, 1961-1966 (2003).
21. World Health Organisation. WHO inter-country consultation influenza A/H5N1 in humans in Asia. http://www.who.int/csr/disease/avian_influenza/ H5N1%20Intercountry%20Assessment%20final.pdf (2005).
22. Ferguson, N. M., Mallett, S., Jackson, H., Roberts, N. & Ward, P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 51, 977-990 (2003).
23. Herlocher, M. L. et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190, 1627-1630 (2004).
24. Oakridge National Laboratory. Landscan global population data. http://www.ornl.gov/sci/gist/landscan (2003).
25. National Statistical Office Thailand. Population Census 2000. http://web.nso.go.th/pop2000/pop_e2000.htm (2000).
26. National Statistical Office Thailand. Population and Labor Statistics. http://web.nso.go.th/eng/stat/subject/subject.htm#cata1 (1999).
27. National Statistical Office Thailand. National Migration Survey. http://web.nso.go.th/eng/stat/migrant/migrant.htm and http://opr.princeton.edu/ archive/nmst/ (1994).
28. Chamratrithirong, A. et al. National Migration Survey of Thailand (Institute for Population and Social Research, Mahidol Univ., Bangkok, 1995).
29. Ministry of Labour Thailand. Yearbook of Labour Statistics. http://www1.mol.go.th/download/chap031-2.pdf (2003).
30. Axtell, R. L. Zipf distribution of U.S. firm sizes. Science 293, 1818-1820 (2001).
31. Moser, M. R. et al. An outbreak of influenza aboard a commercial airliner. Am. J. Epidemiol. 110, 1-6 (1979).
32. Fraser, C., Riley, S., Anderson, R. M. & Ferguson, N. M. Factors that make an infectious disease outbreak controllable. Proc. Natl Acad. Sci. USA 101, 6146-6151 (2004).
33. Hayden, F. G. et al. Use of the oral neuraminidase inhibitor Oseltamivir in experimental human influenza. J. Am. Med. Assoc. 282, 1240-1246 (1999).
34. Carrat, F. et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch. Intern. Med. 162, 1842-1848 (2002).
35. Cauchemez, S., Carrat, F., Viboud, C., Valleron, A. J. & Boelle, P. Y. A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Stat. Med. 23, 3469-3487 (2004).
36. Flahault, A. et al. Modelling the 1985 influenza epidemic in France. Stat. Med. 7, 1147-1155 (1988).
37. Yang, Y., Longini, I. M. & Halloran, M. E. Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups. Department of Biostatistics, Emory University, Technical Report 04-09 http://www.sph.emory.edu/bios/tech/Tech_Report_04-09.pdf (2004).